- Home
- NFJ vs AUPH Comparison
NFJ vs AUPH Comparison
Compare NFJ & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFJ
- AUPH
- Stock Information
- Founded
- NFJ 2005
- AUPH 1993
- Country
- NFJ United States
- AUPH Canada
- Employees
- NFJ N/A
- AUPH N/A
- Industry
- NFJ Finance: Consumer Services
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- NFJ Finance
- AUPH Health Care
- Exchange
- NFJ Nasdaq
- AUPH Nasdaq
- Market Cap
- NFJ 1.2B
- AUPH 1.1B
- IPO Year
- NFJ N/A
- AUPH 1999
- Fundamental
- Price
- NFJ $12.14
- AUPH $8.04
- Analyst Decision
- NFJ
- AUPH Strong Buy
- Analyst Count
- NFJ 0
- AUPH 2
- Target Price
- NFJ N/A
- AUPH $11.50
- AVG Volume (30 Days)
- NFJ 223.5K
- AUPH 1.5M
- Earning Date
- NFJ 01-01-0001
- AUPH 05-01-2025
- Dividend Yield
- NFJ 9.01%
- AUPH N/A
- EPS Growth
- NFJ N/A
- AUPH N/A
- EPS
- NFJ N/A
- AUPH 0.04
- Revenue
- NFJ N/A
- AUPH $235,133,000.00
- Revenue This Year
- NFJ N/A
- AUPH $11.86
- Revenue Next Year
- NFJ N/A
- AUPH $24.96
- P/E Ratio
- NFJ N/A
- AUPH $201.38
- Revenue Growth
- NFJ N/A
- AUPH 33.97
- 52 Week Low
- NFJ $10.45
- AUPH $4.71
- 52 Week High
- NFJ $12.86
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- NFJ 40.29
- AUPH 44.55
- Support Level
- NFJ $12.07
- AUPH $8.37
- Resistance Level
- NFJ $12.26
- AUPH $8.73
- Average True Range (ATR)
- NFJ 0.15
- AUPH 0.23
- MACD
- NFJ 0.01
- AUPH -0.02
- Stochastic Oscillator
- NFJ 50.34
- AUPH 13.75
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. Its primary investment objective is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.